191 related articles for article (PubMed ID: 32213382)
1. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
2. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Vaclova T; Grazini U; Ward L; O'Neill D; Markovets A; Huang X; Chmielecki J; Hartmaier R; Thress KS; Smith PD; Barrett JC; Downward J; de Bruin EC
Nat Commun; 2021 Mar; 12(1):1780. PubMed ID: 33741979
[TBL] [Abstract][Full Text] [Related]
4. Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib.
Wang H; Pan R; Zhang X; Si X; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):594-602. PubMed ID: 31943845
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
Wakuda K; Yamaguchi H; Kenmotsu H; Fukuda M; Takeshita M; Suetsugu T; Kirita K; Ebi N; Hataji O; Miura S; Chibana K; Okamoto I; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
BMC Cancer; 2020 May; 20(1):370. PubMed ID: 32357848
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
[TBL] [Abstract][Full Text] [Related]
7. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Gray JE; Okamoto I; Sriuranpong V; Vansteenkiste J; Imamura F; Lee JS; Pang YK; Cobo M; Kasahara K; Cheng Y; Nogami N; Cho EK; Su WC; Zhang G; Huang X; Li-Sucholeiki X; Lentrichia B; Dearden S; Jenkins S; Saggese M; Rukazenkov Y; Ramalingam SS
Clin Cancer Res; 2019 Nov; 25(22):6644-6652. PubMed ID: 31439584
[TBL] [Abstract][Full Text] [Related]
8. Uncommon
Okuma Y; Shimokawa M; Hashimoto K; Mizutani H; Wakui H; Murakami S; Atagi S; Minato K; Seike M; Ohe Y; Kubota K;
Future Oncol; 2022 Feb; 18(5):523-531. PubMed ID: 35034503
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
Bennouna J; Girard N; Audigier-Valette C; le Thuaut A; Gervais R; Masson P; Marcq M; Molinier O; Cortot A; Debieuvre D; Cadranel J; Lena H; Moro-Sibilot D; Chouaid C; Mennecier B; Urban T; Sagan C; Perrier L; Barlesi F; Denis MG
Clin Lung Cancer; 2020 Jan; 21(1):e10-e14. PubMed ID: 31648999
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).
Akamatsu H; Teraoka S; Morita S; Katakami N; Tachihara M; Daga H; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2019 Jul; 20(4):e492-e494. PubMed ID: 31085043
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
Johnson M; Serra Traynor C; Vishwanathan K; Overend P; Hartmaier R; Markovets A; Chmielecki J; Mugundu GM; Barrett JC; Tomkinson H; Ramalingam SS
Clin Pharmacol Ther; 2024 Feb; 115(2):349-360. PubMed ID: 38010260
[TBL] [Abstract][Full Text] [Related]
13. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
[TBL] [Abstract][Full Text] [Related]
14. Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer.
Hori T; Yamamoto K; Ito T; Ikushima S; Omura T; Yano I
Invest New Drugs; 2024 Jun; 42(3):281-288. PubMed ID: 38536543
[TBL] [Abstract][Full Text] [Related]
15. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC.
Cheng ML; Lau CJ; Milan MSD; Supplee JG; Riess JW; Bradbury PA; Jänne PA; Oxnard GR; Paweletz CP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250387
[TBL] [Abstract][Full Text] [Related]
16. Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.
Park CK; Lee SY; Lee JC; Choi CM; Lee SY; Jang TW; Oh IJ; Kim YC
Thorac Cancer; 2021 Feb; 12(4):444-452. PubMed ID: 33270375
[TBL] [Abstract][Full Text] [Related]
17. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Krug AK; Enderle D; Karlovich C; Priewasser T; Bentink S; Spiel A; Brinkmann K; Emenegger J; Grimm DG; Castellanos-Rizaldos E; Goldman JW; Sequist LV; Soria JC; Camidge DR; Gadgeel SM; Wakelee HA; Raponi M; Noerholm M; Skog J
Ann Oncol; 2018 Mar; 29(3):700-706. PubMed ID: 29216356
[TBL] [Abstract][Full Text] [Related]
18. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
Husain H; Melnikova VO; Kosco K; Woodward B; More S; Pingle SC; Weihe E; Park BH; Tewari M; Erlander MG; Cohen E; Lippman SM; Kurzrock R
Clin Cancer Res; 2017 Aug; 23(16):4716-4723. PubMed ID: 28420725
[No Abstract] [Full Text] [Related]
19. Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for
Gibson AJW; Dean ML; Litt I; Box A; Cheung WY; Navani V
Curr Oncol; 2024 Apr; 31(5):2427-2440. PubMed ID: 38785463
[No Abstract] [Full Text] [Related]
20. Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in
Schuler M; Hense J; Darwiche K; Michels S; Hautzel H; Kobe C; Lueong S; Metzenmacher M; Herold T; Zaun G; Laue K; Drzezga A; Theegarten D; Nensa F; Wolf J; Herrmann K; Wiesweg M
J Nucl Med; 2024 Jun; 65(6):851-855. PubMed ID: 38575188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]